GLAXOSMITHKLINE UNVEILS NEW PAXIL FOR BABIES

(LONDON) – Despite disastrous press surrounding their current $3B fraud settlement, the British pharmaceutical giant GlaxoSmithKlein is moving ahead with the release of a controversial new product: antidepressants for babies.

On behalf of GSK, I want to reiterate that we have learnt from the mistakes that were made. We’re eager to put this unfortunate business behind us and move ahead.” said Chief Executive Sir Andrew Witty at an unveiling “That’s why we are excited to unveil our latest product: NatalPax, antidepressants for babies.”

Read More